• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Positive Results from Mayo Clinic Sponsored Prospective Multi-center Trial in Lung Transplant Patients

Positive Results from Mayo Clinic Sponsored Prospective Multi-center Trial in Lung Transplant Patients

by Zina | Jun 20, 2018 | News

Cellvizio’s optical biopsy could become a safe and effective alternative to invasive biopsies in transplanted patients Mauna Kea Technologies today announced the publication of a prospective multicenter study (ClinicalTrials.gov Identifier: NCT01033201)...
20 Presentations Highlighting Cellvizio’s® Clinical Value in Evaluating IBDs and Pancreatic Cysts at DDW 2018

20 Presentations Highlighting Cellvizio’s® Clinical Value in Evaluating IBDs and Pancreatic Cysts at DDW 2018

by Zina | May 31, 2018 | News

Twenty accepted abstracts demonstrate growing clinical adoption and recognition of Cellvizio as a necessary tool for real-time optical biopsy in multiple gastrointestinal indications Mauna Kea Technologies today announced 20 abstracts supporting Cellvizio® to...
Mauna Kea Technologies obtains first ever FDA clearance for applications of Cellvizio® Confocal Laser Endomicroscopy in Neurosurgery

Mauna Kea Technologies obtains first ever FDA clearance for applications of Cellvizio® Confocal Laser Endomicroscopy in Neurosurgery

by Zina | May 24, 2018 | News

Pivotal regulatory milestone in high stakes applications Cellvizio first-to-market in key neurosurgery field Provides unique response to unmet needs during brain and spinal surgeries Mauna Kea Technologies today announced that it has received U.S. Food and Drug...
Cellvizio® Demonstrates Superior Identification of Patients at Risk for Esophageal Cancer Compared to Current Diagnostic Standard

Cellvizio® Demonstrates Superior Identification of Patients at Risk for Esophageal Cancer Compared to Current Diagnostic Standard

by Zina | Apr 13, 2018 | News

Results from new clinical study that enrolled 172 patients at 8 non-academic centers in the United-States was presented at 2018 World Congress of Endoscopic Surgery hosted by SAGES and CAGS on Thursday, April 12, 2018 at 1:30 PM PDT Mauna Kea Technologies today...
Mauna Kea platform shows anatomical structures that may be important in cancer metastasis.

Mauna Kea platform shows anatomical structures that may be important in cancer metastasis.

by Zina | Apr 11, 2018 | Press Coverage

A Cellvizio pCLE platform was used by the team to generate in vivo histological images of the extrahepatic bile duct adjacent to the liver, during pancreato-biliary surgeries on twelve patients. Samples were then resected and immediately rescanned using...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025
  • Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 
  • Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}